UG earnings analysis
What we found in UG's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
United-Guardian delivered 10% Q2 net-sales growth to $3,108,000, led by a 44% increase in cosmetic and sexual wellness ingredients and partially offset by a 28% decline in medical lubricants. However, gross margin declined to 50% from 53% as a percentage of sales, while reported EPS was $0.16. Liquidity and cash generation improved materially, with first-half operating cash flow of $2,124,531 and working capital of $10,977,452, but the company remains exposed to customer concentration in India and the nonrecurring nature of the $339,493 Renacidin settlement product benefit.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Grew 10% in Q2
- Net sales increased $270,042, or 10%, in Q2 2026 versus Q2 2025, and increased $661,137, or 12%, for the first half of 2026 versus the first half of 2025.
- Ingredients Segment Drove Growth
- Cosmetic and sexual wellness ingredient sales rose $390,150, or 44%, in Q2 and $536,417, or 34%, in the first half, led by a $286,282, or 38%, Q2 increase from ASI.
- Pharmaceutical Sales Improved
- Pharmaceutical net sales increased $16,663, or 1%, in Q2 and $292,173, or 11%, for the first half; Renacidin gross sales increased $22,821, or 1%, in Q2 and $312,752, or 10%, year to date.
- Q2 Operating Expenses Declined
- Operating expenses declined $26,768, or 4%, in Q2, primarily due to lower sales and marketing travel, consulting fees, and the 401K discretionary contribution.
- Operating Cash Flow Strengthened
- Operating cash flow increased to $2,124,531 in the first half of 2026 from $625,323 in the first half of 2025, helped by higher net income, lower inventories, and lower prepaid income taxes.
- Liquidity Position Remained Strong
- Working capital increased $445,376 to $10,977,452 at June 30, 2026 from $10,532,076 at December 31, 2025, while the current ratio remained 7.3 to 1.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Gross Margin Contracted
- Cost of sales rose to 50% of net sales in Q2 2026 from 47% in Q2 2025, reducing gross margin by 3 percentage points. For the first half, cost of sales increased to 50% from 46%, a 4-point deterioration, due primarily to higher overhead costs per unit.
- India Customer Orders Declined
- Medical lubricant sales declined $136,771, or 28%, in Q2 and $167,453, or 15%, in the first half, primarily because of reduced orders from the company’s largest customer in India.
- Settlement Benefit Is Nonrecurring
- The Q2 settlement benefit included $36,360 of product received from the Renacidin contract manufacturer, following $303,133 received in March 2026; the manufacturer has fulfilled its obligation, so the benefit is nonrecurring.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.16
- Gross margin
- 50%
- Segment
- Pharmaceuticals: Q2 net sales increased $16,663, or 1%, year over year; six-month net sales increased $292,173, or 11%.
- Segment
- Cosmetic and sexual wellness ingredients: Q2 sales increased $390,150, or 44%, year over year; six-month sales increased $536,417, or 34%.
- Segment
- Medical lubricants: Q2 sales decreased $136,771, or 28%, year over year; six-month sales decreased $167,453, or 15%.
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management stated working capital is sufficient for at least the next 12 months, expects the effective tax rate to remain 21% for the current fiscal year, and expects to continue using cash for dividends, marketable securities, and growth opportunities.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- United-Guardian reported a solid performance in Q1 2026, with revenues increasing by approximately 16% year-over-year to $2,962,000. Despite challenges in the medical lubricants segment, pharmaceutical sales drove…
- 10-K · March 27, 2026
- United-Guardian describes a product-innovation strategy focused on specialty hydrogel ingredients (Lubrajel) and a small pharmaceuticals franchise (Renacidin) with distribution partnerships to scale reach. Fiscal 2025…
- 10-K · March 21, 2025
- United-Guardian, Inc. reported a total revenue of $2,477,000 for the fiscal year ending December 31, 2024, reflecting a growth trajectory, particularly in cosmetic ingredient sales which constituted 45% of total…
- 10-Q · May 13, 2024
- Q1 2024 revenue increased to $3,254,944 (+$684,620 vs Q1 2023) driven by a surge in cosmetic ingredient sales. Gross margin compressed to ~52.2% from ~57.5% a year ago while operating margin was roughly stable at…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing UG makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever